Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:CGC NASDAQ:EPRX NASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.70$4.71$3.35▼$17.94$124.74M3.93225,772 shs210,923 shsCGCCanopy Growth$1.00$1.04$0.84▼$2.38$448.42M0.796.43 million shs16.30 million shsEPRXEupraxia Pharmaceuticals$6.69$6.78$4.88▼$9.32$434.98M1.05434,332 shs359,470 shsKMDAKamada$7.50$7.70$6.50▼$9.35$431.29M0.8536,717 shs17,985 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+19.00%+49.61%+32.56%-57.84%CGCCanopy Growth0.00%+7.07%-2.44%0.00%-15.97%EPRXEupraxia Pharmaceuticals0.00%+1.53%+5.69%-6.69%+22.30%KMDAKamada0.00%+3.31%+1.49%-11.45%-3.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.70$4.71$3.35▼$17.94$124.74M3.93225,772 shs210,923 shsCGCCanopy Growth$1.00$1.04$0.84▼$2.38$448.42M0.796.43 million shs16.30 million shsEPRXEupraxia Pharmaceuticals$6.69$6.78$4.88▼$9.32$434.98M1.05434,332 shs359,470 shsKMDAKamada$7.50$7.70$6.50▼$9.35$431.29M0.8536,717 shs17,985 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics0.00%+19.00%+49.61%+32.56%-57.84%CGCCanopy Growth0.00%+7.07%-2.44%0.00%-15.97%EPRXEupraxia Pharmaceuticals0.00%+1.53%+5.69%-6.69%+22.30%KMDAKamada0.00%+3.31%+1.49%-11.45%-3.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70245.61% UpsideCGCCanopy Growth 2.17HoldN/AN/AEPRXEupraxia Pharmaceuticals 2.89Moderate Buy$18.00169.06% UpsideKMDAKamada 3.00Buy$12.0060.00% UpsideCurrent Analyst Ratings BreakdownLatest AARD, EPRX, KMDA, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/29/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026EPRXEupraxia Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.006/25/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/15/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026EPRXEupraxia Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.005/18/2026CGCCanopy Growth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.00(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/ACGCCanopy Growth$251.01M1.79N/AN/A$1.13 per share0.88EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AKMDAKamada$181.68M2.37$0.61 per share12.28$4.68 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/ACGCCanopy Growth-$190.29M-$0.59N/AN/AN/A-75.27%-26.95%-17.20%8/7/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.05N/AN/AN/AN/A-87.56%-51.20%8/11/2026 (Estimated)KMDAKamada$20.20M$0.3521.4312.300.6911.21%7.73%5.41%8/12/2026 (Estimated)Latest AARD, EPRX, KMDA, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q4 2026CGCCanopy Growth-$0.06-$0.17-$0.11-$0.05$53.43 million$51.22 million5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/12/2026Q1 2026EPRXEupraxia Pharmaceuticals-$0.22-$0.23-$0.01-$0.23N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AKMDAKamada$0.182.40%N/A51.43%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06CGCCanopy Growth0.313.342.64EPRXEupraxia Pharmaceuticals0.0219.3119.31KMDAKamadaN/A3.331.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ACGCCanopy Growth3.33%EPRXEupraxia PharmaceuticalsN/AKMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ACGCCanopy Growth0.16%EPRXEupraxia PharmaceuticalsN/AKMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.88 millionN/AN/ACGCCanopy Growth3,150448.42 million447.70 millionOptionableEPRXEupraxia Pharmaceuticals2965.02 millionN/AN/AKMDAKamada36057.51 million36.75 millionOptionableAARD, EPRX, KMDA, and CGC HeadlinesRecent News About These CompaniesKamada Ltd Stock GuidanceJuly 3 at 8:42 AM | benzinga.comKamada Posts Solid Q1 2026 Results and Reaffirms Full-Year Guidance as Plasma Expansion AdvancesJune 29, 2026 | theglobeandmail.comKamada (NASDAQ:KMDA) Stock Passes Below Two Hundred Day Moving Average - What's Next?June 27, 2026 | americanbankingnews.comKamada Sets August 5, 2026 Annual General Meeting to Vote on Board, Option Plan and AuditorJune 18, 2026 | tipranks.comKamada: Undervalued, Yet Execution Risks Keep It A HoldJune 2, 2026 | seekingalpha.comKamada Wins FDA Nod for New In‑House Rabies Antibody Testing LabJune 1, 2026 | tipranks.comKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing LaboratoryJune 1, 2026 | globenewswire.comKamada Ltd Earnings Call Balances Growth And RisksMay 19, 2026 | tipranks.comKamada Ltd. (NASDAQ:KMDA) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comKamada (KMDA) Q1 2026 Earnings TranscriptMay 13, 2026 | finance.yahoo.comKamada (KMDA) misses Q1 earnings and revenue estimatesMay 13, 2026 | msn.comKamada Ltd. (KMDA) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comKamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesMay 13, 2026 | zacks.comKamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the YearMay 13, 2026 | globenewswire.comStay Ahead of the Game With Kamada (KMDA) Q1 Earnings: Wall Street's Insights on Key MetricsMay 8, 2026 | finance.yahoo.comKamada to Report First-Quarter 2026 Results on May 13May 6, 2026 | tipranks.comKamada to Announce First Quarter 2026 Financial Results on May 13, 2026May 6, 2026 | globenewswire.comDavid Tsur Takes A Bullish Stance, Acquiring $113K Worth Of Kamada Stock OptionsApril 10, 2026 | benzinga.comEran Nir Sees Potential Growth And Acquires $178K In Kamada Stock OptionsApril 10, 2026 | benzinga.comKamada Ltd Earnings Call Signals Confident Growth PathApril 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAARD, EPRX, KMDA, and CGC Company DescriptionsAardvark Therapeutics NASDAQ:AARD$5.70 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.61 -0.09 (-1.58%) As of 07/2/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Canopy Growth NASDAQ:CGC$1.00 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.00 +0.00 (+0.50%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Eupraxia Pharmaceuticals NASDAQ:EPRX$6.69 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$6.70 +0.00 (+0.07%) As of 07/2/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Kamada NASDAQ:KMDA$7.50 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.50 0.00 (-0.07%) As of 07/2/2026 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
